JOHN H. KLEIN

J O H N H K L E I N @ M S N . C O M

Business Intelligence EPR/CPR prebuilt digital solutions and algorithms.

Strategic & Operational planning and execution, digital ecosystem for company performance

2012 - MARCH 2023

Partner/Chairman/Founder

Bi-Logix, LLC

JANUARY 2021 - PRESENT

Independent Strategic Consultant & Advisor

Research and submission to FDA for NDA approval of combination drug therapies for difficult patient conditions when multiple drugs are required for treatment. Unique packing for patients & doctors.

2011 - 2017

Managing Partner/CEO/Founder

CTT

Generic drugs manufactured at ten contractors around the world and sold as well as distributed in the U.S.

Dava purchased by ENDO Pharmaceuticals for $600 million. Guggenheim Partners lead outside investor.

2005 - 2012

Chairman/CEO/Founder

Dava Pharmaceuticals, Inc

242 nursing homes, 90 acute care hospital, nationwide rehab centers

Represented Franklin Mutual & Appaloosa Mgmt.

2002 - 2010

Lead Independent Director

Kindred Healthcare, Inc

Concentrated in novel unique drug delivery systems. 2002 - 2004

Chairman/Director

NovaDel Pharma, Inc.

(Merged into Aiimlitics)

Copyrighted Digital BI/AI Platforms for application in business enterprise analysis and execution.

MARCH 2023 - PRESENT

Founder/CEO/Managing Partner

Aiimlitics (merged from Bi-Logic,LLC)

Development company of digital platforms for health care and wellness constructed to build a digital twin.

OCT 2021 - PRESENT

Founder/CEO/Managing Partner

Digital Health Technology

T A M P A, F L O R I D A

Focused on business intelligence strategies software solutions for business planning, execution and measuring performance focusing on pharmaceutical and technology companies.

Strategic Business & Technology Solutions

Chairman/Director/Founder

1999 - 2011 (Merged into Bi-Logix, LLC)

Business & supply solutions offered over the internet directly to physician’s offices.

Customer base of 65000 offices; was setup as a tracking stock and absorbed into Andrx, Inc.

1998 - 2000

Chairman/Director

Cyber, Inc.

PBM for nursing homes, HMO’s, clinics and small employee groups.

IPO completed in 1996, revenues rose to form $242 million in 1997 to over $450 million in 1998.

1996 - 1998

Chairman/CEO

MIM, Crop

Shareholder value increased over $1.0 billion.

Revenues over $2.0 Billion with more than 1800 employees. Drugs, Devices, Diagnostics

1995 - 1997

President

IVAX, NA

Leading generic drug manufacturer.

Grew revenues from $34M to over $250M in 5 years.

Sold the company to IVAX for $600M.

Lead investor, Michael Price, Franklin Mutual Series. 1990 - 1995

CEO/President/Director

Zenith Labs, Corp

Manufacturing and distribution of micro connectors for the commercial and the defense industry.

3 plants located in California, New York and Germany 1988 - 1990

President

Viking Technologies

Manufacturing and distribution of micro connectors around the world.

Grew from $30 million to over $800 million

Grew from 4 plants to 34 plants in 17 different countries. 1977 - 1988

Vice President of Operations

Molex, Inc.

Achievements

Earned: BS and MBA from Roosevelt University in Chicago. Earned: Additional graduate studies at USC.

Earned: Additional studies in Strategic Decision Making in Marketing for CEO's at Wharton.

Awarded Copyrights Covering: Broad spectrum of business analytics and applications for BI/AI Digital Platforms.

Member of the US Army Special Operations with an Honorable Discharge. Awarded: Product champion of the year at Molex for development and launch of new product for AT&T.

Awarded: Medal of Honor Ellis Island

Elected Vice Chairman & Chairman of Worldwide generics industry. Awarded: outstanding CEO honor by Mitchell & Co.

Awarded: 11th place in Top 100 CEO's by Forbes for increasing shareholder value. Awarded: bronze standing by Wall Street Transcripts for enhancing enterprise value.

Awarded: Corporate Turnaround of the year for Zenith Labs, Inc. Trustee of Hackensack Meridian University Medical Center Credited: with over 300 generic drug approvals, three NDA's, Five IND's, 400 supplements & amendments and a device FDA approved. Chairman and board member of Worldwide Generic Pharmaceutical Association Trustee and prior President of Board of Dwight Englewood Private College Prep School.

Worked with Knowledge consultants from Stanford, California on developing methods to use in operations in order to improve competitiveness worldwide (Molex is in three case studies).

Experiences In: FDA, DOD, CMS, SAP systems, startups, medium to large companies, IPO's, Private & Public Company Operations, International Operations, all aspects of R&D Industry experienced in Health Care Services, Financial Analysis, Devices, Pharmaceuticals and industries of chemicals, metals, plastics, retail, micro electronics and software.

Operational Experiences In: US, Asia, Europe, India, Southeast Asia, Caribbean, Canada and the Middle East.

Lecturer to MBA program: Columbia University - Strategic Planning and execution. Worked with Harvard Business School on strategic methods to be used in operations to improve competitiveness worldwide.

Published to Trump administration program to enhance and protect pharmaceutical supply chain.

CHARITIES INVOLVED WITH & CONTRIBUTED TO:

Triple Negative Breast Cancer; Alzheimer's/Dementia; Crohn's Colitis; Bergen Family Center; Wounded Warriors; Multiple Sclerosis Society; Police Benevolent Association; American Diabetes Association; American Heart Association; Asperger/Autism Network; Endometriosis Cancer Research

Contact this candidate